“Peptide therapy” is a loose marketing term, not a single approved treatment. It covers everything from topical cosmetic peptides to injectable research compounds. Many of the injectable peptides discussed under this label are unapproved and investigational, with mostly preclinical evidence, so the term hides a wide and uneven range of risk.

What do people mean by peptide therapy?

The phrase gets used for very different things. At one end are topical cosmetic peptides in serums, established skincare ingredients you can read about in the Cleveland Clinic’s overview of peptides for skin. At the other end are injectable research peptides marketed through clinics and online communities. Lumping them together under one tidy label is where confusion starts.

Peptides themselves are just short chains of amino acids. That biological fact does not make any particular “therapy” safe, proven, or approved. The honest version of the term is “a category of products and compounds, some cosmetic and common, some investigational and not approved for human use.” Which one someone means changes everything about the caveats that apply.

Log Notes. This article explains how the term is used and the caveats around it. It gives no dose, preparation, or injection guidance, and nothing here is medical advice. Candidacy, dosing, and safety are decisions for a licensed professional.

What are the caveats?

The biggest caveat is approval status. Many injectable peptides promoted under “peptide therapy” are not approved for human use. BPC-157 is a clear example: it is investigational, and in 2023 the FDA placed it in Category 2 of bulk drug substances under section 503A, the group it will take enforcement action against in compounding, citing insufficient human safety data. You can read more in our note on what BPC-157 is. “Research chemical” framing should never be read as a safety endorsement.

The second caveat is evidence. A lot of what circulates is preclinical, from cell cultures and animal studies, plus anecdote. That is not the same as proven human benefit. The topical end of the spectrum, like copper peptides, is better established as a cosmetic ingredient, which is exactly why collapsing the whole category into one promise is misleading.

How should a careful self-tracker approach it?

With clear language and honest records. Separate the cosmetic from the investigational, treat reported effects as “studied,” not settled, and keep every actual decision with a licensed professional who knows your history. The provider conversation, not a marketing page, is where candidacy and safety belong.

A simple habit helps here. Whenever you meet the phrase, mentally replace it with the specific peptide and its approval status. “Peptide therapy” sounds settled and clinical; “an investigational compound the FDA has not approved for human use” does not, and the second is often the more accurate description of what is actually being sold.

If you are documenting something under that professional guidance, a tidy private record helps you stay honest. In Dosefi you can log each entry with its date and notes and review your own trends over a cycle. Keeping a record never makes a compound approved or a protocol safe; it only ensures your notes are dated, organized, and yours to review.

A grounded takeaway

“Peptide therapy” is an umbrella term spanning common cosmetic peptides and unapproved investigational compounds. The label alone tells you almost nothing about safety or evidence. Ask which peptide, in what form, with what approval status, and route every decision to a licensed professional. Education and honest documentation are the right scope; the term itself deserves skepticism.

Sources